Stock Market 7 February 2026

SpaceX shares last traded at $185, above their $135 IPO price but down from a recent high of $225.64. ARK’s buying of SpaceX has linked Tesla and ETF flows, complicating fund exposure. Mechanical tests are the next step for SpaceX. In healthcare, AbbVie is close to acquiring Apogee Therapeutics for $10.9 billion in cash, with an announcement possible soon. The healthcare ETF XLV fell almost 3% for the week ended June 18, and biotechnology stocks remain sensitive to interest rates. The Financial Select Sector SPDR rose 0.4% last week, trailing the S&P 500’s 0.9% gain, while regional banks dropped about 2.2%. The Federal Reserve kept rates at 3.50%-3.75% but signaled a possible hike later in the year. S&P 500 industrials gained 2.6% over the four-day week, outperforming the broader index, helped by cheaper oil that reduced transport costs, though concerns persist about future rate increases. The Energy Select Sector SPDR Fund fell 6.6%, mirroring losses in large U.S. energy stocks, as Brent crude dropped 7.7% to $80.57 a barrel. Iran continues to influence oil markets. The Nasdaq rose 2.4% for the week, ahead of the S&P 500. Micron will report results soon, and new inflation and GDP data are expected. There are renewed concerns about shipping through the Strait of Hormuz. HIVE Digital Technologies has delivered strong returns, with a 1-year total return of 178.15% and a 90-day gain of 138.13%, but is seen as expensive despite this momentum.